MannKind (MNKD) News Today

MannKind Corporation (NASDAQ: MNKD) is trading lower today. Key drivers: a Q1 earnings and revenue miss that pressured sentiment, offset partly by a new inhaled-program collaboration with United Therapeutics and mixed analyst moves (one bank raised its target, another trimmed it). Volume is elevated, suggesting active positioning around the release and analyst headlines.

• Positive Sentiment: MannKind and United Therapeutics expanded work on a ralinepag dry powder inhalation (DPI) program for pulmonary hypertension and fibrotic lung diseases; United Therapeutics made an additional $5M payment, will be primary manufacturer, and MannKind is eligible for up to $35M in development milestones plus 10% royalties — a clear commercial and cash-flow positive development. Ralinepag DPI Program
• Positive Sentiment: Royal Bank of Canada raised its price target to $4.75 and kept a "sector perform" rating — the higher target signals some analyst confidence and implies upside from current levels. RBC Price Target Raise
• Neutral Sentiment: Mizuho trimmed its target from $8.00 to $7.00 but maintained an "outperform" rating — mixed signal (lower target vs. still bullish stance). Mizuho Target Change The Fly
• Neutral Sentiment: Company published its Q1 earnings slide deck and conference-call materials — useful for investors dissecting guidance, unit trends, and pipeline timelines. Q1 Presentation
• Neutral Sentiment: Deep-dive commentary and analysis pieces (e.g., Seeking Alpha’s "MannKind: It's Complicated") discuss strategic and valuation complexities — may influence longer-term sentiment but are not immediate catalysts. Seeking Alpha Analysis
• Negative Sentiment: Q1 results: EPS of ($0.05) missed consensus ($0.02) and revenue of $90.17M missed expectations (~$105.4M); although revenue rose ~15% year-over-year, the profit shortfall and revenue miss are near-term negative drivers. Q1 Press Release / Slides Zacks Q1 Coverage